On April 7, 2026 TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, reported that it has entered into an agreement with an institutional healthcare investor for financing of up to $20 million. The arrangement comprises pre-paid advances of up to $6 million and a three-year Standby Equity Purchase Agreement (SEPA) providing the Company the right to sell up to $14 million of its common stock to the investor, subject to certain conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The financing agreement provides TransCode with financial flexibility and ensures that TransCode can maintain operational momentum as we conduct our Phase 2a trial for our lead clinical program, TTX-MC138," said Dr. Philippe P Calais, Pharm.D., Ph.D., Chairman and CEO of TransCode. "This runway extension should enable the Company to complete the Phase 2a study and subsequently explore a strategic collaboration for the program," said Tom Fitzgerald, CFO of TransCode.

About TTX-MC138

TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode’s Phase 0 clinical trial produced evidence of delivery of a radiolabeled version of TTX-MC138 to metastatic lesions and pharmacodynamic activity, even at a microdose of the drug candidate, suggesting a broad therapeutic window for TTX-MC138. In the Company’s Phase 1a clinical trial, TTX-MC138 met its safety endpoint and was well tolerated by patients. A Phase 2a clinical trial with TTX-MC138 is expected to begin in the second quarter 2026.

About the Financing Transaction

The pre-paid advance will be evidenced by convertible promissory notes priced at 95% of face value. TransCode will issue a $1 million principal amount note concurrently with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and, subject to certain closing conditions, will issue an additional $5 million principal amount note upon shareholder approval of the transaction as required by Nasdaq rules. The advance will accrue interest at a simple annual rate of 5% and may be converted into TransCode’s common stock.

Upon conversion or repayment of the convertible notes, TransCode at its option may sell up to $14 million of its common stock to the investor under terms specified in the financing agreement.

The financing agreement can be found in TransCode’s Form 8-K filed with the U.S Securities and Exchange Commission.

Tungsten Advisors acted as the Sole Placement Agent.

(Press release, TransCode Therapeutics, APR 7, 2026, View Source [SID1234664212])

On April 7, 2026 Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, and Siemens Healthineers, reported the signing of a supply agreement in which Siemens Healthineers will radiolabel and distribute RAD101 with Fluorine-18 (18F). RAD101 is Radiopharm’s novel imaging small molecule targeting fatty acid synthase (FASN) radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from solid tumors of different origins.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This partnership marks a milestone for Radiopharm, as we bring RAD101 closer to improving diagnostic precision for brain metastases," said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. "We have made considerable progress advancing RAD101 through the clinic, and the second interim analysis showed 90% (18/20) of the patients dosed with RAD101 achieved concordance between PET imaging and MRI (the primary endpoint). The results showed significant and selective tumor uptake in the brain metastases. Images confirm metabolic activity in brain metastases compared to equivocal MRI findings. In addition, the first five patients with evaluable six-month follow-up and/or biopsy data show a positive trend for sensitivity and specificity (the secondary objectives). This partnership ensures our supply of 18F-labeled RAD101 in the U.S. for the initiation of the multi-center global Phase 3 registrational trial following our readout of topline data in the Phase 2b trial in the first half of 2026."

The company has received U.S. Food and Drug Administration (FDA) Fast Track Designation to distinguish between recurrent disease and the treatment effect of brain metastases originating from solid tumors of different origins, including leptomeningeal disease.

Under the terms of the agreement, Siemens Healthineers will manufacture and distribute doses of 18F-labeled RAD101 to support Radiopharm’s upcoming Phase 3 registrational trial in the U.S.

"As the leader in PET imaging solutions, we are pleased to partner with Radiopharm Theranostics to provide our reliable and specialized manufacturing capabilities," said Barry Scott, Head of Radiopharma at Siemens Healthineers. "With our large national network of radiopharmacies in the U.S., we are uniquely qualified and well-equipped to deliver RAD101 as well as other novel PET biomarkers to assist in the fight against challenging diseases such as brain metastases, a condition that more than 300,000 people are diagnosed with in the U.S. each year."

(Press release, Radiopharm Theranostics, APR 7, 2026, View Source [SID1234664228])

On April 7, 2026 Rosalind Franklin University Helix 51 incubator company UP Oncolytics reported encouraging preclinical results in two studies for a novel glioblastoma therapy presented at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on Brain Cancer, held March 23–25 in Philadelphia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The studies highlight the potential of an oncolytic virus-based therapy to both predict treatment response and drive tumor regression in glioblastoma (GBM), one of the deadliest forms of cancer.

GBM remains highly resistant to treatment, with approximately 13,000 new U.S. cases each year and a median survival of just 14 months. Despite broader advances in oncology, no new FDA-approved therapies for GBM have emerged in the past two decades.

UP Oncolytics’ presentations focused on its lead therapy using Zika virus-based oncolytic technology for gliomas:

Predicting treatment response: In the study "Transcriptomic Prediction of Zika Virus Susceptibility in Glioblastoma Cell Lines Using Feature Selection and Machine Learning Approaches," researchers used machine learning to identify and understand genetic and molecular markers associated with tumor sensitivity or resistance to therapy.

"The ability to predict a tumor’s response to treatment ensures patients receive therapies most likely to be effective for their specific disease," said Anna Lundeen, graduate student with UP Oncolytics.

Demonstrating Therapeutic Impact: The study, "Low-neurovirulence wild-type Zika virus strains induce durable tumor regression and survival benefit in patient-derived glioblastoma models," showed complete tumor remission and prolonged survival in in vivo GBM models following treatment.

The research was conducted, in part, in collaboration with RFU’s Center for Cancer Cell Biology, Immunology and Infection, and Center for Proteomics and Molecular Therapeutics, with additional support from the university’s research cores. Ongoing collaboration with RFU is further supported by a recent Illinois Innovation Voucher Program award through the Illinois Science and Technology Coalition and the Illinois Department of Commerce and Economic Opportunity.

"We are pleased with the promising results of these two studies," said Parvez Akhtar, PhD, Chief Scientific Officer of UP Oncolytics. "They promise a new approach to effectively treating GBM tumors while minimizing impact on normal cells. We are working hard to bring this advance to patients."

Janice Urban, PhD, RFU Interim Executive Vice President for Research, added, "UP Oncolytics continues to meet key development milestones, and we are optimistic that this new approach to treating intractable cancer is on the horizon for GBM patients."

(Press release, Rosalind Franklin University, APR 7, 2026, View Source [SID1234664213])

On April 7, 2026 BioOra Limited ("BioOra"), a commercial-stage cell therapy company advancing CAR-T therapies for cancer patients, and Octane Biotech Inc., an Octane Medical Group Company ("Octane"), reported the signing of a Letter of Intent (LOI) to collaborate on the co-development and deployment of advanced cell therapies using the Cocoon automated cell therapy manufacturing platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration builds upon the existing partnership through which BioOra’s CD19-targeted CAR-T therapy (Atla-Cel) is produced by Octane’s Cocoon Platform for patients with relapsed or refractory B-cell lymphoma in New Zealand as part of the registration trial (ENABLE-2). Under the agreement, BioOra and Octane will work together to expand manufacturing capacity to support BioOra’s regional growth, beginning with Australia and extending to additional international markets.

Octane is advancing the Cocoon Platform to enable efficient, decentralized scaling of cell therapy manufacturing. In parallel, BioOra is constructing a bespoke cell therapy manufacturing facility in Christchurch New Zealand, the BioOra Health & Technology Centre, designed to concurrently operate Cocoon systems to meet growing regional demand for CAR-T and other advanced cell therapies. By leveraging the automated and integrated design of the Cocoon Platform, the collaboration is expected to improve operational efficiency, increase manufacturing throughput, and reduce vein-to-vein time, supporting a new model for delivering personalized cell therapies.

"BioOra has demonstrated that manufacturing using the Cocoon Platform can support the commercial delivery of CAR-T therapy in New Zealand," said John Robson, Chief Executive Officer of BioOra. "Our new Christchurch facility is designed to scale this model using multiple Cocoon systems. Partnering with Octane allows us to expand into Australia and beyond while improving efficiency and increasing patient access."

"Octane was founded to unlock the full potential of cell therapy production," said Timothy Smith, CEO and co-founder of Octane. "BioOra is setting the standard for how this model can be deployed at scale. By combining Cocoon-enabled automation with BioOra’s leading clinical and manufacturing infrastructure, we are building a more efficient, scalable paradigm that has the potential to redefine access to cell therapies globally."

The collaboration is also expected to expand international patient access through therapy delivery in New Zealand, and potentially in Australia, where BioOra is establishing partnerships to deliver CAR-T therapies to the large number of patients who do not have access in their home countries.

As part of the collaboration, BioOra and Octane intend to develop closed, integrated, end-to-end manufacturing solutions spanning cell collection, automated processing, and final product release for BioOra cell therapy products. These innovations are designed to simplify manufacturing workflows, further improving the accessibility and practicality of CAR-T therapy.

"CAR-T therapies have demonstrated extraordinary potential to cure otherwise lethal cancers, but scaling access has been limited by manufacturing complexity," said Laurence Cooper, MD, PhD, CAR-T pioneer, and Board Member of BioOra. "Aligning automation with advanced therapeutics through the Cocoon Platform can dramatically expand access. This collaboration fits directly with BioOra’s vision of becoming the first commercial CAR-T company in the Southern Hemisphere, bringing these transformative therapies to far more patients."

The collaboration will focus on:

Scaling BioOra’s CAR-T manufacturing operations in New Zealand using the Cocoon Platform
Expanding manufacturing into Australia and North America to support regional patient access
Developing additional cell therapy programs for deployment on the Cocoon Platform
Co-developing production efficiencies to further automate CAR-T manufacturing solutions
The companies expect to formalize additional development and commercialization agreements following the execution of definitive collaboration agreements.

(Press release, BioOra, APR 7, 2026, View Source [SID1234664229])

On April 7, 2026 Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, reported a collaboration and license agreement with Biogen Inc. for the use of Alloy’s novel and proprietary AntiClastic ASO Platform. Through this collaboration, Biogen will apply the platform to advance antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligible for additional milestone payments and tiered royalties on any products resulting from the collaboration.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration and license agreement brings together Biogen’s scientific leadership and experience in advancing innovative medicines with Alloy’s proprietary antisense discovery capabilities. Alloy’s AntiClastic ASO platform enables drug developers to realize the full potential of antisense therapeutics by reaching intracellular disease targets at the RNA level. The platform is specifically designed to address potency and therapeutic index challenges that have historically held back the promise of antisense drugs due to limited biodistribution and, therefore, efficacy.

"Biogen has built an extraordinary reputation for scientific leadership and for translating breakthrough research into impactful therapies," said Errik Anderson, CEO and Founder of Alloy Therapeutics. "We value our long-standing relationship and are honored to support their world-class teams with access to our AntiClastic ASO Platform and broader technology ecosystem, helping enable the continued pursuit of innovative treatments that have the potential to change patients’ lives."

"This collaboration reflects Biogen’s commitment to pushing the boundaries of scientific innovation and exploring novel approaches to address complex diseases," said Jane Grogan, Ph.D., Executive Vice President and Head of Research at Biogen. "Partnering with Alloy allows us to expand our research strategies and continue advancing programs with the potential to benefit patients worldwide."

Alloy’s capabilities span an integrated ecosystem of drug discovery platforms designed to accelerate the development of innovative therapeutics. The company continues to integrate advanced technologies, including computational and AI-enabled approaches, to enhance discovery and optimization across its programs.

About the Alloy Therapeutics Genetic Medicines AntiClastic ASO Platform

The AntiClastic ASO platform designs novel oligonucleotide formats, exclusively available through partnerships with Alloy’s Genetic Medicines division, to overcome potency and therapeutic index challenges that have historically limited the promise of antisense drugs. Dr. Sudhir Agrawal invented the core technology, which combines improvements in the primary sequence with a proprietary spatial conformation of nucleic acid drugs to promote the delivery of antisense to target RNA, mitigate the inflammatory response, and improve a drug’s therapeutic index. The resulting drug candidates have shown a significant increase in potency compared to gapmer antisense formats. Partners can apply this format to existing antisense sequences or partner to discover new AntiClastic oligonucleotide molecules to precisely deliver therapeutic payloads to their intended target.

(Press release, Alloy Therapeutics, APR 7, 2026, View Source [SID1234664198])